What is Ginkgo Bioworks Holdings (DNA) stock price today?

Ginkgo Bioworks Holdings (DNA) currently trades at $9.70 per share. The stock has a market capitalization of $551.05M and a P/E ratio of —x.

Is DNA stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Ginkgo Bioworks Holdings has a Smart Value Score of 29/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Ginkgo Bioworks Holdings's revenue and earnings?

Ginkgo Bioworks Holdings has trailing twelve-month (TTM) revenue of $170.16M with profit margins of -183.80%. Earnings per share (EPS) is $-5.64.

Is DNA stock overvalued or undervalued?

Based on our DCF model, Ginkgo Bioworks Holdings's intrinsic value is $14.03, representing a margin of safety of 33.36%. The stock currently trades at a P/E of —x.

DNA

Ginkgo Bioworks Holdings

NYSE: DNA · HEALTHCARE · BIOTECHNOLOGY

$9.70

+14.66% today

Updated 2026-05-01

Market cap

$551.05M

P/E ratio

—

P/S ratio

3.24x

EPS (TTM)

$-5.64

Dividend yield

—

52W range

$5 – $18

Volume

1.2M

Market cap

$551.05M

P/E ratio

—

P/S ratio

3.24x

EPS (TTM)

$-5.64

Dividend yield

—

52W range

$5 – $18

Volume

1.2M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

2.7

Growth

5.0

Quality

C+

2.0

Profitability

6.7

Valuation

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →204 stocks currently score above 75

Price targets

Analyst target

$8.67

-10.62%

12-Month target

—

Intrinsic (DCF)

$14.03

Margin of safety

+33.36%

0 Strong Buy1 Buy0 Hold1 Sell2 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ 33.36% below intrinsic value

Risks

- Thin margins at -183.80%

- Negative free cash flow $-63.00M

- Revenue declining -23.80% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$477.71M	$251.46M	$227.04M	$170.16M	$170.16M
Net income	$-2.10B	$-892.87M	$-547.03M	$-312.76M	$-80.75M
EPS	—	—	—	—	$-5.64
Free cash flow	$-304.47M	$-336.30M	$-382.13M	$-178.72M	$-63.00M
Profit margin	-440.63%	-355.08%	-240.94%	-183.81%	-183.80%

Recent insider activity

Date	Insider	Type	Shares	Price
2026-04-09	SHETTY, RESHMA P.	Sale	13,116	$6.40
2026-04-09	KELLY, JASON R	Sale	109,767	$6.40
2026-04-09	CANTON, BARRY	Sale	13,116	$6.40

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
DNA	$551.05M	29	2.7	2.0	6.7	5.0	+33.36%	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-41.61%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-26.29%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.35%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Ginkgo Bioworks Holdings trades at $9.70. Our Smart Value Score of 29/100 indicates the stock is weak. TTM revenue stands at $170.16M. with profit margins at -183.80%. Our DCF model estimates intrinsic value at $14.03.

Frequently asked questions

What is Ginkgo Bioworks Holdings's stock price?

Ginkgo Bioworks Holdings (DNA) trades at $9.70.

Is Ginkgo Bioworks Holdings overvalued?

Smart Value Score 29/100 (Grade F, Strong Sell). DCF value $14.03.

What is the price target of Ginkgo Bioworks Holdings (DNA)?

The analyst target price is $8.67, representing -10.6% downside from the current price of $9.70.

What is the intrinsic value of Ginkgo Bioworks Holdings (DNA)?

Based on our DCF model, intrinsic value is $14.03, a +33.4% margin of safety versus $9.70.

What is Ginkgo Bioworks Holdings's revenue?

TTM revenue is $170.16M.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNYSE

CurrencyUSD

Quick metrics

P/S ratio3.24x

ROE-51.10%

Beta1.57

50D MA$7.31

200D MA$10.05

Shares out0.05B

Float0.04B

Short ratio—

Avg volume1.2M

Performance

1 week-6.99%

1 month+43.25%

3 months-16.76%

YTD-5.54%

1 year—

3 years—

5 years—

Compare

DNA vs LLY →DNA vs JNJ →DNA vs ABBV →Stock screener →